MX2016017396A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2016017396A
MX2016017396A MX2016017396A MX2016017396A MX2016017396A MX 2016017396 A MX2016017396 A MX 2016017396A MX 2016017396 A MX2016017396 A MX 2016017396A MX 2016017396 A MX2016017396 A MX 2016017396A MX 2016017396 A MX2016017396 A MX 2016017396A
Authority
MX
Mexico
Prior art keywords
combination therapy
alpha
combination
olaratumab
doxorubicin
Prior art date
Application number
MX2016017396A
Other languages
English (en)
Inventor
Loizos Nick
D Shah Gaurav
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of MX2016017396A publication Critical patent/MX2016017396A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Combinación de anticuerpos humanos que se unen al receptor alfa de factor de crecimiento derivado de plaquetas humanas (PDGFR alfa), preferiblemente olaratumab y doxorrubicina como un medicamento para el tratamiento de sarcoma de tejido blando.
MX2016017396A 2014-07-03 2015-06-26 Terapia de combinacion. MX2016017396A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462020427P 2014-07-03 2014-07-03
PCT/US2015/037892 WO2016003789A1 (en) 2014-07-03 2015-06-26 Combination therapy

Publications (1)

Publication Number Publication Date
MX2016017396A true MX2016017396A (es) 2017-05-01

Family

ID=53514434

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017396A MX2016017396A (es) 2014-07-03 2015-06-26 Terapia de combinacion.

Country Status (18)

Country Link
US (1) US20170129958A1 (es)
EP (1) EP3164154A1 (es)
JP (2) JP6446478B2 (es)
KR (1) KR20170012481A (es)
CN (1) CN106470698A (es)
AP (1) AP2016009649A0 (es)
AU (1) AU2015284526B2 (es)
BR (1) BR112016030291A2 (es)
CA (1) CA2950936A1 (es)
EA (1) EA201692564A1 (es)
IL (1) IL249240A0 (es)
MA (1) MA40367A (es)
MX (1) MX2016017396A (es)
NZ (1) NZ727147A (es)
SG (1) SG11201610931YA (es)
TW (1) TWI646974B (es)
WO (1) WO2016003789A1 (es)
ZA (1) ZA201608217B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10711066B2 (en) 2016-07-28 2020-07-14 Elanco Us Inc. Anti-canine platelet derived growth factor receptor alpha antibody
CN116997566A (zh) * 2021-03-19 2023-11-03 伊莱利利公司 用PDGFRα抑制剂治疗癌症的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2238982E (pt) * 2003-06-27 2013-01-22 Astellas Pharma Inc Agente terapêutico para o sarcoma de tecidos moles
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
AU2009214727B2 (en) * 2008-02-12 2014-12-11 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
DK2361085T4 (en) * 2008-11-22 2018-10-08 Hoffmann La Roche USE OF ANTI-VEGF ANTIBODY IN COMBINATION WITH CHEMOTHERY TO TREAT CANCER CANCER
JP2013526852A (ja) * 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー

Also Published As

Publication number Publication date
IL249240A0 (en) 2017-02-28
EP3164154A1 (en) 2017-05-10
JP2019014724A (ja) 2019-01-31
AU2015284526B2 (en) 2018-05-17
CN106470698A (zh) 2017-03-01
NZ727147A (en) 2018-05-25
TWI646974B (zh) 2019-01-11
WO2016003789A1 (en) 2016-01-07
AP2016009649A0 (en) 2016-12-31
JP2017520576A (ja) 2017-07-27
CA2950936A1 (en) 2016-01-07
MA40367A (fr) 2017-05-10
AU2015284526A1 (en) 2016-12-22
EA201692564A1 (ru) 2017-09-29
SG11201610931YA (en) 2017-01-27
JP6446478B2 (ja) 2018-12-26
US20170129958A1 (en) 2017-05-11
KR20170012481A (ko) 2017-02-02
TW201611844A (en) 2016-04-01
BR112016030291A2 (pt) 2017-11-14
ZA201608217B (en) 2019-05-29

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
CA2956871C (en) Compounds active towards bromodomains
MX2017006694A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2016010953A (es) Proteinas de fc multimericas.
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
WO2015130554A3 (en) Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MA40535A (fr) Imagerie et thérapie d'une inflammation et d'une infection ciblant hsp90
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
WO2019016597A3 (en) SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES
EP3549582A3 (en) Novel capsazepine analogs for the treatment of cancer and other proliferative diseases
EA201390314A1 (ru) Супернатант, кондиционированный активированными лейкоцитами, и его использование для заживления ран
TN2016000497A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MA40367A (fr) Polythérapie
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
TW201612192A (en) Therapy for GIST
EP3579843A4 (en) 3-BETA-HYDROXY-5-ALPHA-PRÉGNAN-20-ONE FOR USE IN MEDICAL TREATMENT
MX2017001512A (es) Compuestos activos hacia bromodominios.
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis